Globe Newswire02.25.19
Natus Medical Incorporated has implemented a new organizational structure designed to improve operational performance and make it a stronger, more profitable company.
Natus will consolidate its three business units, Neuro, Newborn Care and Otometrics, into “One Natus.” This initiative creates a single, unified company with globally led operational teams in Sales & Marketing, Manufacturing, R&D, Quality, and General and Administrative functions. The new structure provides for increased transparency, efficiency and cross-functional collaboration across common technologies, processes and customer channels.
Specifically, Natus intends to:
In connection with the organizational redesign, Natus has also created three new senior management positions:
Natus entered the NeuroCom market in 2008 via acquisition and will discontinue sales of new products immediately. Natus will continue to support NeuroCom customers with technical support and service and will continue as a leader in the balance diagnostic market with its Otometrics' branded balance products. Revenue from the NeuroCom product line was approximately $7 million during 2018.
“As Natus continues to evolve as a stronger, global medical device company, realigning our organizational structure, reviewing our investment priorities and improving productivity are part of our strategy to increase customer focus and drive long-term value for all of our stakeholders,” said Jonathan Kennedy, president and CEO. “With a new operating model and attention on profitability and our core strengths, we are working to simplify our operations, develop key capabilities and capture maximum value from our assets, while improving our focus on our served markets. Importantly, these enhancements will position us to further exceed our customers' needs and enable Natus to become a more dynamic and competitive organization. I am very confident in the ability of our entire team and the newly formed senior leadership team to execute on the many opportunities that lie ahead.”
As part of the new structure, Carsten Buhl, president and CEO of Otometrics and Leslie McDonnell, vice president and general manager of the Newborn Care business unit, are leaving the company. “On behalf of everyone at Natus, I want to thank Leslie and Carsten for their service and leadership at Natus. Their achievements over the past year have improved our market positions and further strengthened our teams' capabilities. We wish them well in their future endeavors,” Kennedy said.
Natus provides medical devices and services used for the screening, treatment and monitoring of common medical conditions in newborn care, hearing, balance impairment, neurological dysfunction, neurosurgery and sleep disorders.
Natus will consolidate its three business units, Neuro, Newborn Care and Otometrics, into “One Natus.” This initiative creates a single, unified company with globally led operational teams in Sales & Marketing, Manufacturing, R&D, Quality, and General and Administrative functions. The new structure provides for increased transparency, efficiency and cross-functional collaboration across common technologies, processes and customer channels.
Specifically, Natus intends to:
- Continue to execute proven go-to-market strategies within its market specialties of Neuro, Newborn Care and Audiology;
- Prioritize product development and design quality by enhancing focus and discipline, and allow these functions to operate more efficiently and effectively;
- Enhance focus on operational excellence through streamlining processes and developing common platforms throughout the organization; and
- Position the company for growth.
In connection with the organizational redesign, Natus has also created three new senior management positions:
- Austin Noll, executive vice president and chief commercial officer;
- Sean Langan, vice president of Global Operations; and
- Ivan Pandiyan, vice president of Global R&D.
- Drew Davies, executive vice president and chief financial officer;
- D. Christopher Chung, M.D., vice president of Quality, Regulatory Affairs and Chief Medical Officer;
- William Hill, general counsel; and
- Martin Woodrow, vice president of Human Resources.
Natus entered the NeuroCom market in 2008 via acquisition and will discontinue sales of new products immediately. Natus will continue to support NeuroCom customers with technical support and service and will continue as a leader in the balance diagnostic market with its Otometrics' branded balance products. Revenue from the NeuroCom product line was approximately $7 million during 2018.
“As Natus continues to evolve as a stronger, global medical device company, realigning our organizational structure, reviewing our investment priorities and improving productivity are part of our strategy to increase customer focus and drive long-term value for all of our stakeholders,” said Jonathan Kennedy, president and CEO. “With a new operating model and attention on profitability and our core strengths, we are working to simplify our operations, develop key capabilities and capture maximum value from our assets, while improving our focus on our served markets. Importantly, these enhancements will position us to further exceed our customers' needs and enable Natus to become a more dynamic and competitive organization. I am very confident in the ability of our entire team and the newly formed senior leadership team to execute on the many opportunities that lie ahead.”
As part of the new structure, Carsten Buhl, president and CEO of Otometrics and Leslie McDonnell, vice president and general manager of the Newborn Care business unit, are leaving the company. “On behalf of everyone at Natus, I want to thank Leslie and Carsten for their service and leadership at Natus. Their achievements over the past year have improved our market positions and further strengthened our teams' capabilities. We wish them well in their future endeavors,” Kennedy said.
Natus provides medical devices and services used for the screening, treatment and monitoring of common medical conditions in newborn care, hearing, balance impairment, neurological dysfunction, neurosurgery and sleep disorders.